Anixa Biosciences Yönetim
Yönetim kriter kontrolleri 2/4
Anixa Biosciences' CEO is Amit Kumar, appointed in Jul 2017, has a tenure of 7.33 years. total yearly compensation is $3.64M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth $1.89M. The average tenure of the management team and the board of directors is 7.7 years and 6.1 years respectively.
Anahtar bilgiler
Amit Kumar
İcra Kurulu Başkanı
US$3.6m
Toplam tazminat
| CEO maaş yüzdesi | 19.8% |
| CEO görev süresi | 7.3yrs |
| CEO sahipliği | 1.6% |
| Yönetim ortalama görev süresi | 7.7yrs |
| Yönetim Kurulu ortalama görev süresi | 6.1yrs |
Son yönetim güncellemeleri
Recent updates
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -US$12m |
| Apr 30 2024 | n/a | n/a | -US$12m |
| Jan 31 2024 | n/a | n/a | -US$11m |
| Oct 31 2023 | US$4m | US$720k | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$11m |
| Apr 30 2023 | n/a | n/a | -US$11m |
| Jan 31 2023 | n/a | n/a | -US$12m |
| Oct 31 2022 | US$2m | US$631k | -US$14m |
| Jul 31 2022 | n/a | n/a | -US$14m |
| Apr 30 2022 | n/a | n/a | -US$16m |
| Jan 31 2022 | n/a | n/a | -US$15m |
| Oct 31 2021 | US$11m | US$573k | -US$13m |
| Jul 31 2021 | n/a | n/a | -US$11m |
| Apr 30 2021 | n/a | n/a | -US$9m |
| Jan 31 2021 | n/a | n/a | -US$10m |
| Oct 31 2020 | US$2m | US$522k | -US$10m |
| Jul 31 2020 | n/a | n/a | -US$10m |
| Apr 30 2020 | n/a | n/a | -US$9m |
| Jan 31 2020 | n/a | n/a | -US$9m |
| Oct 31 2019 | US$665k | US$476k | -US$12m |
| Jul 31 2019 | n/a | n/a | -US$15m |
| Apr 30 2019 | n/a | n/a | -US$18m |
| Jan 31 2019 | n/a | n/a | -US$17m |
| Oct 31 2018 | US$12m | US$425k | -US$14m |
Tazminat ve Piyasa: Amit's total compensation ($USD3.64M) is above average for companies of similar size in the US market ($USD655.65K).
Tazminat ve Kazançlar: Amit's compensation has increased whilst the company is unprofitable.
CEO
Amit Kumar (60 yo)
7.3yrs
Görev süresi
US$3,639,651
Tazminat
Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 7.3yrs | US$3.64m | 1.61% $ 1.9m | |
| President | 8yrs | US$1.97m | 0.11% $ 128.9k | |
| Senior Vice President of Engineering | 12.2yrs | US$275.00k | Veri yok | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 3.2yrs | Veri yok | Veri yok |
7.7yrs
Ortalama Görev Süresi
64.5yo
Ortalama Yaş
Deneyimli Yönetim: ANIX's management team is seasoned and experienced (7.7 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 12yrs | US$3.64m | 1.61% $ 1.9m | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 1.8yrs | Veri yok | Veri yok | |
| Lead Independent Director | 7.3yrs | US$169.35k | 2.84% $ 3.3m | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 6.1yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 5.1yrs | Veri yok | Veri yok | |
| Member of Breast Cancer Clinical Advisory Board | 1.8yrs | Veri yok | Veri yok | |
| Member of SAB & Breast Cancer Clinical Advisory Board | 6.2yrs | US$169.35k | 0.36% $ 420.9k | |
| Member of Scientific Advisory Board | 6.1yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 6.1yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 6.1yrs | Veri yok | Veri yok | |
| Independent Director | 5.1yrs | US$169.35k | 0.14% $ 167.1k |
6.1yrs
Ortalama Görev Süresi
70yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ANIX's board of directors are considered experienced (6.1 years average tenure).